Aclaris earns revenue from licensing intellectual property and providing laboratory services to third parties. License fees may be upfront; development and regulatory milestones are paid when achieved, and commercial milestones and royalties as sales occur.
10-K for FY2025, filed Feb 26, 2026The Company operates and reports as one reportable segment, which focuses on identifying and developing innovative therapies to address…View ↗
Licenses of Intellectual Property – The Company recognizes revenue received from non-refundable, upfront fees related to the licensing of…View ↗
Milestone and Royalty Payments – The Company considers any future potential milestones and sales-based royalties to be variable…View ↗
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$7.8M
10-K for FY2025, filed Feb 26, 2026
$7.8M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Contract research
|
24%
FY2022: 15%
|
Contract research, FY2025
$1.9M Sources
|
|
|
Licensing
Licensed
|
76%
FY2022: 84%
|
Licensing, FY2025
$6M Sources
|
Licensed |
Third parties license Aclaris intellectual property and use its laboratory research services; Aclaris also seeks partners to develop, obtain approval for, or commercialize drug candidates. Its customers and revenue are based in the United States.
10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates…View ↗
We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates…View ↗
The Company operates and reports as one reportable segment, which focuses on identifying and developing innovative therapies to address…View ↗
No. It lost $64.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$18.5MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
Growing. Revenue grew 16% in 4 years, from $6.8M in FY2021 to $7.8M in FY2025, about 4% a year.
Broader candidate types
The pipeline has broadened from the older report's internally developed, KINect-based drug candidates to include biologic programs, including monoclonal and bispecific antibodies, alongside small-molecule candidates.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026
Loading...